FindTrial
Sign In

JAK expression in Cutaneous Lichen Planus

A study of expression of janus kinase in cutaneous lichen planus. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/09/058125
Enrollment
25
Registered
2023-09-29
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L433- Subacute (active) lichen planus

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Atal Bihari Vajpayee Institute of medical sciences and Dr Ram Manohar Lohia Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with cutaneous lichen planus 2. Disease duration > 6 weeks

Exclusion criteria

Exclusion criteria: 1. Patients on treatment for lichen planus in last 4 weeks 2. Pregnant and lactating women 3. Immunocompromised patients 4. Patients with autoimmune disorders like thyroid disorders, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, vitiligo and vasculitis, and systemic disorders like hypertension, ischaemic heart disease, diabetes mellitus, hepatitis, renal failure, respiratory disorders and urogenital disorders.

Design outcomes

Primary

MeasureTime frame
Expression of JAK 1 & JAK 3 in cutaneous lichen PlanusTimepoint: Baseline—

Secondary

MeasureTime frame
Correlation of expression of JAK1 & JAK 3 with cutaneous lichen planusTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr Kunal Chanana

Atal Bihari Vajpayee Institute of medical sciences and Dr Ram Manohar Lohia Hospital

drpoojamrig@gmail.com9868812525

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026